TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03978273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night-time brace + virtual-brace
Description: Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Night-time brace only
Description: Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180.
Study: NCT00928330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-MCC-DM1
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-MCC-DM1
Description: Intravenous repeating dose
Study: NCT04267640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG0001
Description: AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG0001
Description: AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00238264

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
Study: NCT01560351

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
Study: NCT05229939

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data

Intervention type: OTHER
Intervention: No intervention
Description: Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Study: NCT02419027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI Flora

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00002586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocopherol
Study: NCT02575430

Intervention type: OTHER
Intervention: No treatment: retrospective chart review
Study: NCT00165009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolution clip (endo-clipping device)
Description: Resolution clip (endo-clipping device)
Study: NCT02644408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol（Yining）
Description: Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
Study: NCT03867630

Intervention type: PROCEDURE
Intervention: Transforaminal Block
Description: Epidural block via neural foramen of lumbar spine
Study: NCT02351232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00018902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Standard anti-depressant treatment with the SSRI fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Standard anti-depressant treatment with the SSRI fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Standard antidepressant treatment with the non-SSRI medication venlafaxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Standard antidepressant treatment with the non-SSRI medication venlafaxine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT addresses maladaptive beliefs in order to encourage behavioral change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT addresses maladaptive beliefs in order to encourage behavioral change

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Standard anti-depressant treatment with the SSRI fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Standard anti-depressant treatment with the SSRI fluoxetine
Study: NCT03215784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01221857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord®
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
Study: NCT02562547

Intervention type: DEVICE
Intervention: Hem-Avert Perianal Stabilizer
Description: The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
Study: NCT01291121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal expansile gas and ranibizumab injection
Description: Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
Study: NCT01802086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emla-cream
Description: Topical anaesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Miniderm cream
Description: Topical
Study: NCT04405219

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain
Description: Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain
Description: Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
Study: NCT03078062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administration of a single-dose of Normal saline during spinal anesthesia
Study: NCT00380562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience Corps
Description: High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
Study: NCT04097548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Description: Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
Study: NCT01110187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: 200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
Study: NCT04398745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.
Study: NCT04121286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
Study: NCT01982981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water provision
Description: perception behavioral change at the beginning and at the end of the intervention
Study: NCT01110187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Description: 20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
Study: NCT01838044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin and celecoxib
Description: During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo and celecoxib
Description: Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Study: NCT01982981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water provision
Description: After participants are recruited, drink 2L of water for 8 weeks.
Study: NCT01540760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCAF5352A
Description: Multiple ascending doses
Study: NCT04675047

Intervention type: OTHER
Intervention: no intervention for healthy control
Description: observational study - no intervention
Study: NCT01540760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching MCAF5352A, multiple doses
Study: NCT01884519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit SSW® (2013-2014 season)
Description: 1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit SSW® (2013-2014 season)
Description: 1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
Study: NCT01853566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
Study: NCT00879450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: booklet given to parents for home exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet
Description: booklet given to parents for home exercises
Study: NCT04093037

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #1: Non Invasive Break-Up Time (NIBUT)
Description: A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score
Description: The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #3: Standard Break-Up Time (SBUT)
Description: The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #4: Schirmer test
Description: The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire to the patient
Description: A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
Study: NCT02418637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksite screening for DM, HTN and hyperlipidemia
Description: Six monthly visits to worksite to perform screenings
Study: NCT04018339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing an inert placebo
Study: NCT02196675

Intervention type: DEVICE
Intervention: Endocutter
Description: The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
Study: NCT00805415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (SH T00658L)
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
Study: NCT01330901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
Study: NCT01982591

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT04579549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva Assay
Description: saliva assay test for high concentrations of SARS-CoV-2
Study: NCT03651843

Intervention type: OTHER
Intervention: Questionnaire
Description: Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
Study: NCT02349126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection
Description: ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
Study: NCT04972877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group protocol
Description: For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group protocol
Description: For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes.
Study: NCT01755832

Intervention type: PROCEDURE
Intervention: Pool exercise
Description: Group exercise in heated pool one hour per week for 12 weeks.
Study: NCT01466842

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter ablation using cryothermia
Description: Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.